M. Levent Selamoglu (Executive Chairman)
Levent is a pharmaceutical veteran with more than 25 years of pharma industry experience across Central & Eastern Europe and Middle East & North Africa. Levent was the previous CEO and Chairman of Mustafa Nevzat Pharma (“MN Pharma”), the leading injectable generics pharmaceutical company in CEE. MN Pharma was the first and only company to receive US FDA approval in Turkey and was responsible for the launch and commercialisation of the first biosimilar product in Turkey. MN Pharma was sold to Amgen, one of the world’s largest biotechnology companies, for $700m in 2012. At the time of sale, MN Pharma was fully integrated (including API production), employed 1,200 people and generated approximately $200m in annual revenue. Levent is a non-executive Board Member of Phamactive (generic pharma), Imuneks Pharma (OTC) and Polus Global (Korean biosimilar company). Levent was also recently a senior advisor to Polpharma and currently leads Frontier Pharma’s advisory business in Turkey and Poland.
Kiren Naidoo (Managing Director)
Kiren is a former pharmaceutical industry-focused investment banker, most recently a senior Vice President at Bank of America Merrill Lynch in Johannesburg and London. Kiren’s expertise spans strategic and financial advisory (covering mergers & acquisitions and business development) and capital raising activities (across debt, equity and hybrid products). Kiren’s pharma expertise covers branded generics, specialty pharma and consumer health. Some of Kiren’s most notable transactions include: Sale of MN Pharma to Amgen ($700m), Sale of Bedford Laboratories (owned by Boehringer Ingelheim) to Hikma ($300m), Swap of Boehringer Ingelheim’s Consumer Healthcare Business with Sanofi’s Animal Health Business (Merial) (€22bn) and the Financing of Teva’s $40.5bn acquisition of Allergan Generics (Actavis). Kiren also leads Frontier Pharma’s advisory activities in Central and Eastern Europe, Russia / CIS, Middle East / North Africa, sub-Saharan Africa and Central America.